Friday

20th May 2022

Opinion

Never waste a crisis - so start building Covid research in Africa

  • Addis Ababa, the capital of Ethiopia, is already home to the African Centers for Disease Control (CDC) (Photo: EUobserver)
Listen to article

As European and African heads of state gather in Brussels today and tomorrow (17-18 February) to discuss deepening ties – including the burning issues of equitable access to Covid-19 vaccines and treatments and the need for drug manufacturing in Africa – we, as African and European scientists, believe another issue should feature high on the agenda: the development of robust clinical research infrastructure across the continent.

This is critical, not only to be prepared for future disease outbreaks, but also to support the summit's objectives of building lasting prosperity across Africa.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

Outdated, trickle-down approaches to scientific cooperation, inherited from colonial times, will not work. And the EU-AU summit presents a historic opportunity to do things differently by discussing investment in science infrastructure in Africa.

We speak with the confidence of researchers who have witnessed the outstanding achievements of African scientists who, with adequately resourced research infrastructure, have more than proved their capabilities.

But throughout the Covid-19 pandemic, we have also observed with dismay the lack of proper global investment and coordination in key areas to address the health needs of African communities. Fewer than six percent of clinical trials for Covid-19 worldwide have been carried out in Africa.

This story is not new. The African continent is home to around 15 percent of the world's population and 25 percent of the global disease burden. Yet only 1.1 percent of global investment in health research and development (R&D) is spent in Africa.

This imbalance increases the risk of a brain drain of Africa's talented scientists, who may have no choice but to exercise their skills outside the continent in research environments with better funding and more modern equipment. .

Covid-19 has highlighted the importance of building African clinical research infrastructure to support pandemic response and preparedness.

The Africa Centers for Disease Control (CDC), based in Ethiopia, has played a major role in coordinating pandemic control efforts. We have seen how those African countries with strong medical research capacity were better able to respond to Covid-19.

For example, Botswana was the first country able to detect the emergence of the Omicron variant, thanks to its sequencing capacities.

That is why investing now to strengthen African-based, African-led collaborative research platforms is a smart move. True global pandemic preparedness requires robust infectious disease surveillance and control networks everywhere on the globe, including in the Global South.

Bolstering African research infrastructure will allow the continent – and the world – to respond more effectively when faced with the next infectious threat.

The good news is that African medical research expertise and experience is plentiful; too often missing, however, are the resources and platforms needed to bring that talent together.

Ebola and west Africa

For those diseases for which such platforms do exist, there has been an impressive track record of success. An outstanding example is the response to the 2014-2016 Ebola crisis in west Africa, which saw African and global networks mobilising quickly to conduct robust vaccine research in one of the most difficult social and medical environments ever faced by researchers.

Or take the Democratic Republic of Congo (DRC), where scientists have carried out clinical trials to the highest international standards in extremely remote areas and under challenging conditions. The game-changing drugs they developed for a neglected disease called 'sleeping sickness' have helped the DRC to envision the elimination of a disease that killed hundreds of thousands in the past century.

The ANTICOV consortium is another collaborative medical research initiative in Africa, now testing treatments for patients with mild-to-moderate Covid-19 across 13 African countries with researchers from leading African institutions in the driver's seat.

ANTICOV could be seen as an example of the wider research platforms that we are calling for to connect science and public health institutions, ensure research is relevant to the needs of different countries, support faster development of treatments and testing tools, and later provide rapid response to future disease outbreaks.

Competence, commitment...but frustration

From past successes, we believe that building such a clinical network is within our reach. However, to be sure of achieving this, we need to see sustained investment in the human and technical resources needed to ensure platforms can be flexible, autonomous, able to respond promptly and effectively to emerging outbreaks, and capable of supporting efforts to tackle ongoing health priorities across the continent.

We see enormous competence and commitment among African scientists, but also the frustration and anxiety that comes with not having all the tools needed to respond to future health crises. With dedicated resources and political will, we believe the future of medical research on the continent could be bright.

We need European and African decision makers gathering this week in Brussels to see and harness this potential, to promote scientific excellence, and contribute to a shared healthy future for us all.

Author bio

Samba Sow (former Minister of Health of Mali and director of the Center for Vaccine Development in Bamako), Marie-Paule Kieny (director of research at INSERM in Paris), John Amuasi (Leader, Global Health and Infectious Diseases Research Group, Kumasi Center for Collaborative Research in Tropical Medicine, Ghana), Serge Eholie (Head of infectious diseases at Treichville University Teaching Hospital in Abidjan, Côte d'Ivoire), Francine Ntoumi (founding director of the Congolese Foundation for Medical Research in Brazzaville), Jürgen May (Chairman of Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany), Dieudonné Mumba (head of Parasitology at the National Institute of Biomedical Research in Kinshasa), Bernhards Ogutu (chief research officer at the Kenya Medical Research Institute in Nairobi), Nathalie Strub-Wourgaft (director at the Drugs for Neglected Diseases initiative in Geneva), Marc-Alain Widdowson (director of the Institute of Tropical Medicine in Antwerp) and Yazdan Yazdanpanah (Director of ANRS Emerging Infectious Disease Funding Agency in Paris, France).

Disclaimer

The views expressed in this opinion piece are the author's, not those of EUobserver.

Vaccine-waiver row refuses to die at EU-AU summit

The stark gap in Covid-19 vaccination rates between Europe and Africa is likely to feed into the EU-AU summit negotiations. But a patent waiver still looks like a no-go for Europe.

Don't Look Up - but for vaccines

Netflix's satirical disaster movie, Don't Look Up, is primarily a warning about our failure to act on climate change but it's plot will seem strangely familiar to anyone who has observed the EU approach to Covid-19 vaccines, particularly patent-waivers.

More EU teams needed to prosecute Ukraine war crimes

A Joint Investigation Team combines prosecutors, police and judges from different countries who come together under the coordination of Eurojust to synchronise cross-border investigations —with a track record of achieving results: from the Bataclan attacks to the MH17 investigation.

Georgia, Moldova, Ukraine - the case for granting EU candidacy

Granting EU candidacy status to Georgia, Moldova and Ukraine will firmly anchor their ties with Brussels — and enable the EU to secure its place in the Black Sea region, connecting Europe to China and energy-rich Central Asia, bypassing Russia.

Will 'Putin's Nato' follow Warsaw Pact into obscurity?

Valdimir Putin's equivalent to Nato — the Collective Security Treaty Organization of Russia, Kazakhstan, Kyrgyz Republic, Armenia, Tajikistan, and Belarus — is convening in Moscow next week to give cover that Russia is not alone in its war against Ukraine.

The EU Parliament Covid inquiry: the questions MEPs must ask

A basic lack of transparency around the EU's vaccines procurement negotiations has prevented effective public and parliamentary scrutiny. It has also made it impossible to answer some of the key questions we put forward here.

News in Brief

  1. Half of Gazprom's clients have opened rouble accounts
  2. Macron seeks 'quick' EU answer on Moldova application
  3. German chancellor to tour Western Balkans
  4. UN: more than 8,000 civilians killed or injured in Ukraine
  5. EU agrees new minimum gas storage target
  6. EU justice agency to have more roles on war crimes
  7. More than 50,000 Ukrainians refused entry into EU in 2021
  8. Germany open to EU treaty change 'if required'

Stakeholders' Highlights

  1. Nordic Council of MinistersNordic delegation visits Nordic Bridges in Canada
  2. Nordic Council of MinistersClear to proceed - green shipping corridors in the Nordic Region
  3. Nordic Council of MinistersNordic ministers agree on international climate commitments
  4. UNESDA - SOFT DRINKS EUROPEEfficient waste collection schemes, closed-loop recycling and access to recycled content are crucial to transition to a circular economy in Europe
  5. UiPathNo digital future for the EU without Intelligent Automation? Online briefing Link

Latest News

  1. MEPs urge sanctioning the likes of ex-chancellor Schröder
  2. MEPs call for a more forceful EU response to Kremlin gas cut
  3. Catalan leader slams Pegasus use: 'Perhaps I'm still spied on'
  4. More EU teams needed to prosecute Ukraine war crimes
  5. French EU presidency struggling on asylum reforms
  6. EU states warn of looming food-price crisis
  7. Ultraconservatives in Putin's shadow
  8. Nordic Bridges unveil latest highlights of Spring programme

Join EUobserver

Support quality EU news

Join us